

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

FOSTER ET AL.

Examiner: Javanmard, Sahar

APPLICATION NO: 10/528,688

FILED: MAY 17, 2005

FOR: SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE
TREATMENT OF DEMYELINATING DISORDERS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:


Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-9273

Date: *3rd October 2008*


Cozette McAvoy
Attorney for Applicants
Reg. No. 60,457